Publications by authors named "Yolanda Real"
Article Synopsis
- Around 750,000 patients each year are expected to be cured of HCV infection by 2030, but those with advanced chronic liver disease still face risks of liver issues and liver cancer.
- A study followed 2,335 patients who were treated successfully for HCV and found that a small percentage experienced liver problems and new liver cancer within six years, with risks increasing steadily over time.
- Risk assessment tools like Baveno VII criteria and other HCC algorithms are useful for identifying patients at higher risk for complications after curing HCV, helping tailor surveillance and management strategies.
Background & Aims: Baveno VII has defined a clinically significant (i.e., prognostically meaningful) decrease in liver stiffness measurement (LSM) in cACLD as a decrease of ≥20% associated with a final LSM <20 kPa or any decrease to <10 kPa.
View Article and Find Full Text PDFBackground And Aims: Patients with hepatitis C virus (HCV) and advanced fibrosis remain at risk of hepatocellular carcinoma (HCC) after sustained viral response (SVR) and need lifelong surveillance. Because HCC risk is not homogenous and may decrease with fibrosis regression, we aimed to identify patients with low HCC risk based on the prediction of noninvasive markers and its changes after SVR.
Approach And Results: This is a multicenter cohort study, including patients with HCV and compensated advanced fibrosis that achieved SVR after direct antivirals.
Article Synopsis
- * Researchers applied a new testing protocol to analyze samples from 220 patients across various Spanish hospitals, finding that 88.6% had at least one RAS, with specific patterns linked to different HCV subtypes.
- * The findings reveal that certain patients had RAS not affected by the drugs they received, indicating the necessity for thorough RAS testing, especially since ribavirin treatment did not impact RAS diversity or type.
Aims: Accurate liver fibrosis staging is crucial for the management of chronic hepatitis C (CHC). The invasiveness and cost burden of liver biopsy have driven the search for new noninvasive biomarkers of fibrosis. Based on the link between serum angiopoietin-1 and 2 levels and CHC progression, we aimed to determine the value of these angiogenic factors as noninvasive biomarkers of liver fibrosis.
View Article and Find Full Text PDF